Hence then, the article about perfuse therapeutics announces fda clearance of ind application for phase 1 2a clinical trial of per 001 intravitreal implant in patients with glaucoma was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Perfuse Therapeutics Announces FDA Clearance of IND Application for Phase 1/2a Clinical Trial of PER-001 Intravitreal Implant in Patients with Glaucoma )
Last updated :
Also on site :
- Aura AI Assistant for Unreal Engine Launches: VR Studio Ships Game in Half the Time with New Agent Capabilities
- Man accused of placing pipe bombs near GOP and Democratic headquarters in Washington to remain in jail pending trial
- FDA Clears BrainSpace Intellidrop, an automated neuro device that addresses ICU nursing shortages and builds training data for Physical AI